Valspar Industries, Inc. manufactures industrial coatings and specialty chemical products. The company was founded on December 5, 1888 and is headquartered in Indianapolis, IN.

Based in Vejle, Denmark, Fertin Pharma offers innovative, high-quality pharmaceutical and nutraceutical chewing gum products. Through partnerships with leading global pharma companies, we have consolidated our position as the preferred B2B partner for nicotine chewing gum. As a family-owned company with a unique heritage in chewing gum, we excel in every part of the development and manufacturing processes. We value an open, committed and professional relationship with our collaborators and when partnering with Fertin Pharma, you will experience a company dedicated to the field of medicated chewing gum.

Diabecore Medical, Inc. is a private company headquartered in Toronto, ON, Canada, that develops insulin products for the treatment of diabetes.

Manufactures and markets pharmaceutical capsules through its subsidiaries

GSK Consumer Healthcare SA engages in the development and marketing of pharmaceutical products. The company was founded on May 8, 1991 and is headquartered in Nyon, Switzerland.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health. The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA (dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans. Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The Open-Label Study builds on Chimerix’s extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies. CMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases. Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing. Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs.

Rhone Poulenc Rorer, a subsidiary of Solvay SA, is a French company that manufactures and distributs pharmaceutical products.

R.P. Scherer Technologies LLC, a subsidiary of Catalent, Inc., is an American company that develops, manufactures and sells oral, topical, sterile and inhaled forms of drug delivery products.

Part of GSK Plc, Novartis Consumer Health SA is a Swiss company located in Basel focused on pharmaceutical preparations.

Beijing Times Mingyuan Biotechnology Co., Ltd., established on 2019-10-25, Business scope includes biological,medicine,Technology promotion in the field of information and food processing,Technical Services,technology development,technical consulting,technology transfer;Commissioned processing;sell fresh fruit,fresh vegetables,cosmetic,daily necessities,Disinfection products for daily use,Medical DeviceΙ,Class II,building materials,metallic material,household appliances,electronic product,computer,Software and Auxiliary Equipment,knitted goods,hygiene products,Clothing and shoes,Wujinjiaodian,sporting goods,Equipment,stationery;health management,Health Advisory(Except for medical treatment activities subject to approval);Economic Information Consulting(No intermediary services);sell food;Class III medical device business.(Market entities independently choose business projects in accordance with the law,Carry out business activities;sell food,Class III medical device operation and sales of food and sales of food.and items that are legally subject to approval,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

Intelgenx Corp. develops oral-controlled release pharmaceutical products. The firm offers pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. The company was founded in 2003 and is headquartered in Saint-Laurent, Canada.

SciTech Specialities is a pharmaceutical company that manufactures effervescent granules and tablets using aqueous granulation technology. The company operates two manufacturing facilities for nutraceuticals and pharmaceuticals, and exports products to several countries. It develops and produces Scitech Efferceutical supplements to include all nutrients required for a healthy lifestyle. It was established in Mumbai, Maharashtra, India in 2007.

Nanjing Zhuokang Pharmaceutical Technology Co., Ltd., established on 2017-03-24, Business scope includes medical technology,biotechnology development,Technology Transfer and Technology Consulting;Class I medical device,Chemical reagents and chemical products(Free of Hazardous Chemicals)technology development and sales;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Part of DKSH Holding AG, Refarmed Chemicals SA is a company headquartered in Lugano, Switzerland. The firm manufactures active pharmaceutical ingredients and finished dosage forms. On June 27, 2022 DKSH Management Ltd. acquired Refarmed Chemicals SA.

Johnson & Johnson Consumer, Inc. manufactures health and skin care products. It offers wide variety of lotion, moisturizing cream, baby wash, shampoo and conditioner, baby powder and bath, hand and face wipes, soap, baby oil and cologne. The company was founded on March 8, 2016 and is headquartered in Skillman, NJ.